Rajeev M Menon Selected Research

paritaprevir

2/2019	Pharmacokinetics of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir in Healthy Chinese Subjects and HCV GT1b-Infected Chinese, South Korean and Taiwanese Patients.
2/2019	Effects of chronic kidney disease stage 4, end-stage renal disease, or dialysis on the plasma concentrations of ombitasvir, paritaprevir, ritonavir, and dasabuvir in patients with chronic HCV infection: pharmacokinetic analysis of the phase 3 RUBY-I and RUBY-II trials.
11/2018	Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Hepatitis C Virus-Infected Cirrhotic and Non-cirrhotic Patients: Analyses Across Nine Phase III Studies.
10/2017	Clinical Pharmacokinetics of Paritaprevir.
10/2017	Clinical Pharmacokinetics of Dasabuvir.
4/2017	Effects of Mild and Moderate Renal Impairment on Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir, and Ribavirin Pharmacokinetics in Patients with Chronic HCV Infection.
3/2017	Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir: Drug Interactions With Antiretroviral Agents and Drugs forSubstance Abuse.
1/2017	Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trials.
1/2017	Application of Exposure-Response Analyses to Establish the Pharmacodynamic Similarity of a Once-Daily Regimen to an Approved Twice-Daily Dosing Regimen for the Treatment of HCV Infection.
1/2017	Pharmacokinetics and Tolerability of Anti-Hepatitis C Virus Treatment with Ombitasvir, Paritaprevir, Ritonavir, with or Without Dasabuvir, in Subjects with Renal Impairment.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Rajeev M Menon Research Topics

Disease

20	Infections 02/2019 - 07/2015
10	Chronic Hepatitis C 11/2018 - 07/2015
5	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2021 - 12/2017
5	Neoplasms (Cancer) 01/2021 - 05/2017
4	Fibrosis (Cirrhosis) 02/2019 - 01/2017
4	Body Weight (Weight, Body) 04/2017 - 01/2016
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2021 - 02/2017
2	Virus Diseases (Viral Diseases) 07/2016 - 11/2015
1	Invasive Fungal Infections 01/2021
1	Hematologic Neoplasms (Hematological Malignancy) 01/2021
1	Chronic Kidney Failure (Chronic Renal Failure) 02/2019
1	Chronic Renal Insufficiency 02/2019
1	Hepatic Insufficiency 01/2019
1	Multiple Myeloma 04/2018
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2018
1	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2018
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2018
1	Chromosome Aberrations (Chromosome Abnormalities) 12/2017
1	Substance-Related Disorders (Drug Abuse) 03/2017
1	Hepatitis C 10/2016
1	Breast Neoplasms (Breast Cancer) 02/2016
1	Peripheral Arterial Disease 02/2012

Drug/Important Bio-Agent (IBA)

20	paritaprevirIBA 02/2019 - 07/2015
20	Antiviral Agents (Antivirals)IBA 02/2019 - 07/2015
18	ombitasvirIBA 02/2019 - 07/2015
17	Ritonavir (Norvir)FDA Link 02/2019 - 07/2015
14	dasabuvirIBA 02/2019 - 07/2015
9	venetoclaxIBA 01/2021 - 02/2017
6	Ribavirin (Virazole)FDA LinkGeneric 02/2019 - 01/2016
4	CreatinineIBA 04/2017 - 01/2016
3	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 01/2021 - 01/2016
3	Pharmaceutical PreparationsIBA 02/2019 - 01/2016
3	Proteins (Proteins, Gene)FDA Link 10/2017 - 02/2016
2	posaconazole FDA Link 01/2021 - 02/2017
2	Cytochrome P-450 CYP3AIBA 01/2021 - 02/2017
2	ErbB Receptors (EGF Receptor)IBA 01/2019 - 05/2017
2	Immunoconjugates (Immunoconjugate)IBA 01/2019 - 05/2017
2	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 11/2018 - 02/2016
2	Protease Inhibitors (Protease Inhibitor)IBA 10/2017 - 01/2016
1	EnzymesIBA 01/2021
1	Antineoplastic Agents (Antineoplastics)IBA 01/2021
1	monomethylauristatin FIBA 01/2019
1	EpitopesIBA 01/2019
1	depatuxizumab mafodotinIBA 01/2019
1	Antimitotic AgentsIBA 01/2019
1	Cytotoxins (Cytolysins)IBA 01/2019
1	Anti-Bacterial Agents (Antibiotics)IBA 11/2018
1	Azithromycin (Zithromax)FDA LinkGeneric 11/2018
1	Rituximab (Mabthera)FDA Link 12/2017
1	NucleosidesIBA 10/2017
1	ABT-414IBA 05/2017
1	Methadone (Dolophine)FDA LinkGeneric 03/2017
1	Naloxone Drug Combination Buprenorphine FDA Link 03/2017
1	Cytochrome P-450 CYP3A InhibitorsIBA 02/2017
1	Antifungal AgentsIBA 02/2017
1	TabletsIBA 01/2017
1	InterferonsIBA 01/2017
1	Hypoglycemic Agents (Hypoglycemics)IBA 01/2017
1	Opioid Analgesics (Opioids)IBA 01/2017
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 10/2016
1	Tacrolimus (Prograf)FDA LinkGeneric 10/2016
1	SofosbuvirIBA 02/2016
1	glucose 6-phosphate(transporter)IBA 02/2016
1	Everolimus FDA Link 02/2012

Therapy/Procedure

5	Therapeutics 11/2018 - 01/2016
1	Liver Transplantation 10/2016
1	Stents 02/2012